Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas

• Published in: Science translational medicine Vol. 15; no. 698; p. eade8732
• Main Authors: Kanaya, Nobuhiko, Kitamura, Yohei, Lopez Vazquez, Maria, Franco, Arnaldo, Chen, Kok-Siong, van Schaik, Thijs A, Farzani, Touraj Aligholipour, Borges, Paulo, Ichinose, Toru, Seddiq, Waleed, Kuroda, Shinji, Boland, Genevieve, Jahan, Nusrat, Fisher, David, Wakimoto, Hiroaki, Shah, Khalid
• Format: Journal Article
• Language: English
• Published: United States 31.05.2023
• Subjects: Animals; Brain - pathology; Brain Neoplasms - genetics; Brain Neoplasms - pathology; Brain Neoplasms - therapy; Gene Editing; Granulocyte-Macrophage Colony-Stimulating Factor; Immunotherapy; Melanoma - pathology; Melanoma - therapy; Melanoma, Cutaneous Malignant; Mice; Oncolytic Virotherapy; Oncolytic Viruses - genetics; Proto-Oncogene Proteins B-raf; Simplexvirus - genetics; Stem Cells

Oncolytic virus therapy has shown activity against primary melanomas; however, its efficacy in brain metastases remains challenging, mainly because of the delivery and immunosuppressive nature of tumors in the brain. To address this challenge, we first established PTEN-deficient melanoma brain metas...